Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT01962792 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT01962792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01962792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2013
Completion date
March 31, 2019
Enrollment
84 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma